Gene therapy for cardiovascular diseases

Annals of Medicine

Volumn 28, Issue 2, 1996, Pages 89-94

  Ylä Herttuala, Seppo ^a  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

Atherosclerosis; Gene therapy; Hypercholesterolaemia; Liposomes; Restenosis; Viral vectors

Indexed keywords

ANGIOPLASTY; ATHEROSCLEROSIS; BLOOD VESSEL; BYPASS SURGERY; CARDIOVASCULAR DISEASE; ETHICS; EXPRESSION VECTOR; GENE EXPRESSION; GENE TARGETING; GENE THERAPY; GENE TRANSFER; GENETIC TRANSFECTION; HEMOPHILIA; HUMAN; HYPERCHOLESTEROLEMIA; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RESTENOSIS; REVIEW; THROMBOGENESIS; VASCULAR DISEASE;

EID: 0030005929     PISSN: 07853890     EISSN: None     Source Type: Journal    
DOI: 10.3109/07853899609092931     Document Type: Review

References (28)

1. Uemura K, Pisa Z. Recent trends in cardiovascular disease mortality in 27 industrialized countries. World Health Stat Q 1985; 38: 143-62.
2. Nabel EG, Nabel G. Gene transfer and cardiovascular disease. TCM 1991; Jan/Feb: 12-7.
3. Goldstein JL, Brown MS. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic Basis of Inherited Disease. New York: McGraw-Hill Information Services Co, 1989: 1215-50.
4. Morgan RA, Anderson WF. Human gene therapy. Annu Rev Biochem 1993; 62: 191-217.
5. Mulligan RC. The basic science of gene therapy. Science 1993; 260: 926-32.
6. Miller AD. Human gene therapy comes of age. Nature 1992; 357: 455-60.
7. Friedmann T. Approaches to gene therapy of complex multigenic diseases: cancer as a model and implications for cardiovascular disease and diabetes. Ann Med 1992; 24: 411-7.
8. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993; 362: 801-9.
9. Ueda M, Becker AE, Fujimoto T, Tsukada T. The early phenomena of restenosis following percutaneous transluminal coronary angioplasty. Eur Heart J 1991; 12: 937-45.
10. Grondin CM, Campeau L, Lespérance J, Enjalbert M, Bourassa MG. Comparison of late changes in internal mammary artery and subvenous vein crafts in two consecutive series of patients 10 years after operation. Circulation 1984; 70: 208-12.
11. Simons M, Edelman ER, DeKeyser JL, Langer R, Rosenberg R. Antisense c-myb oligonucleotides inhibit intimal arterial smooth muscle cell accumulation in vivo. Nature 1992; 359: 67-73.
12. Morishita R, Gibbons GH, Ellison KE, et al. Intimal hyperplasia after vascular injury is inhibited by antisense cdk 2 kinase oligonucleotides. J Clin Invest 1994; 93: 1458-64.
13. Indolfi C, Awedimento EV, Rapacciuolo A, et al. Inhibition of cellular ras prevents smooth muscle cell proliferation after vascular injury in vivo. Nat Med 1995; 1: 541-5.
14. Morishita R, Gibbons GH, Horiuchi M, et al. A gene therapy strategy using a transcription factor decoy of the E2F binding site inhibits smooth muscle proliferation in vivo. Proc Natl Acad Sci USA 1995; 92: 5855-9.
15. Ohno T, Gordon D, San H, et al. Gene therapy for vascular smooth muscle cell proliferation after arterial injury. Science 1994; 265: 781-4.
16. Chang MW, Barr E, Seltzer J, et al. Cytostatic gene therapy for vascular proliferative disorders with a constitutively active form of the retinoblastoma gene product. Science 1995; 267: 518-22.
17. Symons RH. Small catalytic RNAs. Annu Rev Biochem 1992; 61: 641-71.
18. von der Leyen HE, Gibbons GH, Morishita R, et al. Gene therapy inhibiting neointimal vascular lesion: in vivo transfer of endothelial cell nitric oxide synthase gene. Proc Natl Acad Sci USA 1995; 92: 1137-41.
19. Nabel EG, Yang Z, Liptay S, et al. Recombinant platelet-derived growth factor B gene expression in porcine arteries induces intimal hyperplasia in vivo. J Clin Invest 1993; 91: 1822-9.
20. Nabel EG, Yang Z, Plautz G, et al. Recombinant fibroblast growth factor-1 promotes intimal hyperplasia and angiogenesis in arteries in vivo. Nature 1993; 362: 844-6.
21. Nabel EG, Shum L, Pompili VJ, et al. Direct transfer of transforming growth factor β1 gene into arteries stimulates fibrocellular hyperplasia. Proc Natl Acad Sci USA 1993; 90: 10759-63.
22. Ylä-Herttuala S, Luoma J, Viita H, Hiltunen T, Sisto T, Nikkari T. Transfer of 15-lipoxygenase gene into rabbit iliac arteries results in the appearance of oxidation-specific lipid-protein adducts characteristic of oxidized low density lipoprotein. J Clin Invest 1995; 95: 2692-8.
23. Rome JJ, Shauani V, Flugelman MY, et al. Anatomic barriers influence the distribution of in vivo gene transfer into the arterial wall. Arterioscler Thromb 1994; 14: 148-61.
24. Ylä-Herttuala S, Nikkari T, Hirvonen J, et al. Biochemical composition of coronary arteries in Finnish children. Arteriosclerosis 1986; 6: 230-6.
25. Chowdhury JR, Grossman M, Gupta S, Chowdhury NR, Baker JR, Wilson JM. Long-term improvement of hypercholesterolemia after ex vivo gene therapy in LDLR-deficient rabbits. Science 1991; 254: 1802-5.
26. Grossman M, Rader DJ, Muller DWM, et al. A pilot study of ex vivo gene therapy for homozygous familial hypercholesterolaemia. Nat Med 1995; 1: 1148-54.
27. Kozarsky KF, McKinley DR, Austin LL, Raper SE, Stratford-Perricaudet LD, Wilson JM. In vivo correction of low density lipoprotein receptor deficiency in the watanabe heritable hyperlipidemic rabbit with recombinant adenoviruses. J Biol Chem 1994; 269: 13695-702.
28. Kay MA, Rothenberg S, Landen CN, et al. In vivo gene therapy of hemophilia B: sustained partial correction in factor IX-deficient dogs. Science 1993; 262: 117-9.